Closing

Do GIP/GLP-1 & amylin agonists improve all-cause mortality versus placebo?

Mostly studied in type 2 & unspecified diabetes.

Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →

Where the evidence stands

Doubtful. So far, one result, not yet repeated.

NoUnsureYes
Belief
0.35 (range 0.10–0.55)
Trials for
1
Trials against
0
Inconclusive
1

Already under way

The evidence so far

Registered trials
15
With posted results
2
Published papers
5

Of 3 decided analyses: 1 favor gip/glp-1 & amylin agonists, 2 find no difference, 0 favor the comparator.

Papers

Trials

See every trial in the evidence map →